|CD International Enterprises, Inc. (CDII) Success Driven by Bold Vision|
- Global medical marijuana sales to grow over 17 percent annually to more than $55 billion by 2025
- CDII one of first companies to market CBD to Chinese consumers
- CDII has extensive business relationships in China – knows Chinese commerce and consumer
- Led by Dr. James Wang – over a decade of success with Chinese businesses
With more than a decade of experience internationally sourcing and distributing industrial commodities such as iron ore, manganese ore, and scrap metals for delivery to businesses in the People’s Republic of China, CD International Enterprises (OTC: CDII) has developed extensive global relationships which have given the company the uncommon ability to identify and capitalize on emerging market opportunities.
Under the leadership of Dr. James Wang, chairman and CEO, CD International has demonstrated repeated success at navigating complex logistical and legal issues to globally source and deliver industrial commodities while maintaining margins and keeping both buyers and sellers of commodities satisfied. Last month alone, the Florida-based company announced full corporate offers to purchase commodities valued in excess of $350 million at current market prices. With a brash, bold initiative, CDII is now expanding into new lucrative territory.
The company’s long success and vision are in no small part attributable to Wang’s comprehensive background and leadership. Wang earned bachelor’s and master of science degrees in China before earning his Ph.D. from the University of Arizona in 1994. He started his career as a research scientist and assistant professor at the University of Minnesota School of Medicine. With a passion and acumen for business, Wang left science, gained vast experience and achieved success at several companies. He has led CD International since its inception in 2006.
With a keen eye for exceptional global market opportunities, Wang and his team have expanded CDII into one of the fastest growing markets in the world, medical marijuana. Global medical marijuana sales are projected to grow at a compound annual growth rate of over 17 percent to more than $55 billion by 2025. To facilitate such a bold initiative and become one of the first to distribute and sell medicinal cannabidiol (CBD) based products to a global population of two billion-plus Chinese-speaking people, the company recently formed its Green Products division and online retail store (http://www.greencbdproducts.com/cbd). Non-euphoric CBD-based products have a broad range of clinically proven therapeutic uses, including treating epilepsy, anxiety, pain and nausea. CBD oil is legal in 29 U.S. states and can be exported to over 40 countries, including China.
Wang and his team have extensive, long established business relationships in China as well as expansive knowledge of the innate practices of the Chinese consumer and Chinese commerce. This gives CD International real competitive advantages in a fast-developing global market. Given the bold vision and history of success of Wang and his team at CDII, it’s hard to believe they won’t exceed expectations again.
Learn more about the company, its subsidiary, mineral trading and consulting divisions, and growing online CBD products store by going to http://www.cdii.net.
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com